CAS 154361-50-9|Capecitabine
Introduction：Basic information about CAS 154361-50-9|Capecitabine, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Capecitabine | ||
|---|---|---|---|
| CAS Number | 154361-50-9 | Molecular Weight | 359.350 |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 517.6±60.0 °C at 760 mmHg |
| Molecular Formula | C15H22FN3O6 | Melting Point | 110-121°C |
| MSDS | ChineseUSA | Flash Point | 266.8±32.9 °C |
| Symbol | GHS08 | Signal Word | Danger |
Names
| Name | capecitabine |
|---|---|
| Synonym | More Synonyms |
Capecitabine BiologicalActivity
| Description | Capecitabine is an oral prodrug that is converted to its active metabolite, fluorouracil (FU), by thymidine phosphorylase. |
|---|---|
| Related Catalog | Signaling Pathways >>Cell Cycle/DNA Damage >>DNA/RNA SynthesisSignaling Pathways >>Cell Cycle/DNA Damage >>Nucleoside Antimetabolite/AnalogResearch Areas >>Cancer |
| Target | DNA/RNA Synthesis[1] |
| In Vitro | Capecitabine is an anti-cancer chemotherapy drug. It is classified as an antimetabolite. Capecitabine is converted into 5′-deoxy-5-fluorocytidine (5′DFCR), 5′-deoxy-5-fluorouridine (5′DFUR) and 5-fluorouracil (5-FU) by carboxylesterases (CES1 and 2), cytidine deaminase (CDD), and thymidine phosphorylase (TP), in both liver and tumour. Capecitabine induces a significant cytotoxic effect in vitro only at high concentrations. Mean IC50 values vary from 860 μM in COLO205 cells to 6000 μM in HCT8 cells[2]. |
| In Vivo | A pharmacokinetic/pharmacodynamic study is carried out in mice bearing HCT 116 xenografts receiving 0.52 and 2.1 mmol/kg/d of Capecitabine by oral gavage. Capecitabine administered at 0.52 mmol/kg/day induces partial control of HCT 116 xenografts tumour growth: growth rate =7.5±0.5 on day 21. Capecitabine 2.1 mmol/kg/day achieves complete control of tumor growth during the treatment period: growth rate =1±0.2 on day 21[2]. |
| Cell Assay | HCT 116, HCT8, HCT15, HT29, SW620 and COLO205 human colon cancer cells are used. Cells are plated on day 1 in 96-well plates at a density of 2500 cells/well for HCT 116, 3500 cells/well for HCT8 and HT29, 5000 cells/well for HCT15, 6000 cells/well for SW620 and 7000 cells/wells for COLO205 in a volume of 150 μL/well. All cell lines are treated on day 2 with increasing concentrations of Capecitabine (0.1-10 mM), 5′DFCR (10 nM-100 μM), 5′DFUR (2.5-500 μM) or 5-FU (0.5-250 μM) for 24 h. After drug exposure, cells are washed once with cold PBS and placed in 200 μL of drug-free medium for 72 h after the end of drug exposure. The cells are then fixed with trichloroacetic acid and stained with sulforhodamine B. Optical densities are measured at 540 nm with a Biohit BP-800. The results are based on three independent experiments performed in triplicate[2]. |
| Animal Admin | Mice[2] Six-week-old C57/Bl6 Nu/Nu mice are used. Bilateral HCT 116 xenografts are obtained by subcutaneous injection of 107 cells/flank. Animals bearing HCT 116 xenografts are treated with vehicle or Capecitabine 0.52 or 2.1 mmol/kg (563 and 2250 mg/m2, respectively) given once daily for 5 consecutive days/week by oral gavage for 3 weeks (days 0-4, 7-11, 14-18). Animals are culled on day 0 at 15, 30 min, 1, 2, 4, 8 and 24 h, and prior to planned treatment on days 7 and 14 after the start of treatment. Three animals per time-point are analysed. At the time of collection, blood is collected in heparin, and plasma isolated and stored at −80°C. The liver is removed immediately and stored in RNAlater solution. Tumours are macro-dissected to remove fibrotic tissue and blood vessels and snap-frozen in liquid nitrogen. |
| References | [1]. PharmD CM, et al. Capecitabine: A review. Clinical Therapeutics. 2005 Jan; 27(1): 23-44. [2]. Guichard SM, et al. Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity. Eur J Cancer. 2008 Jan;44(2):310-7. |
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 517.6±60.0 °C at 760 mmHg |
| Melting Point | 110-121°C |
| Molecular Formula | C15H22FN3O6 |
| Molecular Weight | 359.350 |
| Flash Point | 266.8±32.9 °C |
| Exact Mass | 359.149261 |
| PSA | 122.91000 |
| LogP | 0.97 |
| Vapour Pressure | 0.0±3.1 mmHg at 25°C |
| Index of Refraction | 1.600 |
| InChIKey | GAGWJHPBXLXJQN-UORFTKCHSA-N |
| SMILES | CCCCCOC(=O)Nc1nc(=O)n(C2OC(C)C(O)C2O)cc1F |
| Storage condition | -20°C Freezer |
Safety Information
| Symbol | GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H341-H350-H360FD |
| Precautionary Statements | P201-P308 + P313 |
| Hazard Codes | T |
| Risk Phrases | 45-60-61-68 |
| Safety Phrases | 53-22-36/37-45 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
| HS Code | 2934999090 |
Customs
| HS Code | 2934999090 |
|---|---|
| Summary | 2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles84
More Articles| Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument. Dis. Colon Rectum 57(8) , 958-66, (2014) Until recently, no studies have prospectively evaluated bowel function after sphincter-preserving surgery for rectal cancer with the use of a validated bowel function scoring system.The aim of this st... | |
| [A case of S-1/CDDP-resistant recurrent gastric cancer responsive to capecitabine/CDDP]. Gan To Kagaku Ryoho. 41(5) , 649-51, (2014) We present a case of recurrent gastric cancer in which stable disease status was achieved for four months due to treatment with capecitabine/cisplatin (CDDP)after the failure of multiple anticancer dr... | |
| Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J. Clin. Oncol. 32(10) , 1031-9, (2014) Fluourouracil (FU) is a mainstay of chemotherapy, although toxicities are common. Genetic biomarkers have been used to predict these adverse events, but their utility is uncertain.We tested candidate ... |
Synonyms
| 2(1H)-Pyrimidinone, 1-(5-deoxypentofuranosyl)-5-fluoro-4-[[(pentyloxy)carbonyl]amino]- |
| 1-(5-Deoxypentofuranosyl)-5-fluoro-4-{[(pentyloxy)carbonyl]amino}-2(1H)-pyrimidinone |
| 5'-Deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine |
| Capecitabine |
| 5'-Deoxy-5-fluoro-N4-[(pentyloxy)carbonyl]cytidine |
| Capecytabine |
| Ro 09-1978 |
| Captabin |
| MFCD00930626 |
| XELODA |
| RO-9-1978 |
| Cpecitabine |
| Capecitibine |
| 1-(5-deoxypentofuranosyl)-5-fluoro-4-{[(pentyloxy)carbonyl]amino}pyrimidin-2(1h)-one |
| Ro 09-1978/000 |
